WeTrials

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of FWD1509 MsOH in Advanced Non-Small Cell Lung Cancer

What is this study?

This study is testing a new medication called FWD1509 MsOH for people with advanced lung cancer. Researchers want to find out the safest dose to use and how well it helps fight the disease.

Who can participate?

You may be able to join if you have advanced non-small cell lung cancer that has spread, and you have a cancer tissue sample available for testing.

What will happen?

Participants will receive the study medication while doctors closely monitor their safety and health throughout the process. The main goal is to find the right dose of the drug.

Where and when?

The study has locations in Canton, Ohio, and Houston, Texas, and its current status is listed as unknown.

Key Points
  • 1Tests a new investigational lung cancer drug
  • 2Helps find the safest and most effective dose
  • 3Open to patients with advanced lung cancer

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Carcinoma, Non-Small-Cell Lung

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.